The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
https://european-biotechnology.com/wp-content/uploads/2024/07/Bildschirmfoto_2024-07-09_um_09.31.12.png634956Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-07-09 07:34:442024-07-16 18:30:54EMA-Gate: PharmaMar wins suit against EMA